If you experience signs of an allergic reaction, kidney problems, pancreatitis, severe abdominal pain, gallstones, or gallbladder inflammation, contact your healthcare provider right away or seek emergency medical care
This Phase 3 trial, completed in December of the previous year, enrolled participants with obesity and knee osteoarthritis
Metabolic associated fatty liver disease is a risk factor for chronic kidney disease
GLP-1 Compounded Medications Targeted by Connecticut Attorney General On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications